Your session is about to expire
← Back to Search
Alpha-2 Adrenergic Agonist
Phase 1: Atipamezole & caffeine's in a 1:1 ratio for Emergence From Anesthesia
Phase 1
Waitlist Available
Research Sponsored by University of Chicago
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up this test will be repeated every 15 minutes for 90 minutes after the subject has awakened]
Summary
This trial is testing if a combination of Atipamezole and caffeine can help healthy people wake up faster from anesthesia. Atipamezole reverses sedation, and caffeine increases alertness.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ this test will be repeated every 15 minutes for 90 minutes after the subject has awakened]
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~this test will be repeated every 15 minutes for 90 minutes after the subject has awakened]
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
The time when the drug injections are complete to the awakening of the subject.
Secondary study objectives
Measure Cognitive Function
Measure Reaction Time
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: Phase 1: Atipamezole & caffeine's in a 1:1 ratioActive Control1 Intervention
Is this arm, subjects will be randomized to IV administration of Atipamezole \& caffeine's in a 1:1 ratio
Group II: Phase 1: Precedex & Saline in a 1:1 ratioPlacebo Group1 Intervention
Is this arm, subjects will be randomized to receive IV administration of Precedex \& Saline in a 1:1 ratio
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
University of ChicagoLead Sponsor
1,052 Previous Clinical Trials
759,039 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger